Correction: Etelcalcetide in patients on hemodialysis with severe secondary hyperparathyroidism. multicenter study in “real life” (J. Clin. Med., (2019) 8, 7, 10.3390/jcm8071066)

Abstract

The authors wish to make the following corrections to the previous publication [1] in the text, Tables 1 and 2, and also Figure 1. In the text on page 2, it is reported that “The following levels of serum calcium were used for the definition of hypocalcemia: < 7.0 mEq/L; = 7.0 but = 7.5 mEq/L; = 7.5 but < 8.3 mEq/L”. This statement needs to be corrected: “The following levels of serum calcium were used for the definition of hypocalcemia: < 7.0 mg/dL; = 7.0 but = 7.5 mg/dL; > 7.5 but < 8.3 mg/dL”. We wish to correct the caption of Table 1 where serum calcium concentrations are reported as mEq/L instead of mg/dL. (Table Presented) The caption of the amended Table 1 is: (Table Presented) We wish to correct the caption of Table 2 where serum calcium concentrations are reported as mEq/L instead of mg/dL and etelcalcetide is reported as Parsabiv (trade name). (Table Presented) The caption of the amended Table 2 is: (Table Presented) We wish to correct the caption of Figure 1 where serum calcium concentrations are reported as mEq/L instead of mg/dL. (Figure Presented) The caption of the amended Figure 1 is: (Figure Presented) The authors apologize to the readers for any inconvenience caused by these changes. It is important to state that this correction does not affect our study's results and involves no changes or modifications in the original data supporting our results. The original manuscript [1] will remain online on the article webpage, with reference to this Correction.